Alpha Cognition Inc (ACOG)

Nov 18, 2024

Alpha Cognition announces equity offering and warrant adjustments - Investing.com

Nov 18, 2024

Nov 17, 2024

Opening Day: Invizyne Technologies jumps after IPO - MSN

Nov 17, 2024

Nov 15, 2024

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update - Business Wire

Nov 15, 2024

Nov 15, 2024

Alpha Cognition director Leonard Mertz acquires $49,996 in shares By Investing.com - Investing.com South Africa

Nov 15, 2024

Nov 15, 2024

Alpha cognition CEO Michael McFadden acquires shares worth $14,996 - Investing.com

Nov 15, 2024

Nov 15, 2024

Alpha cognition director John Havens buys $24,995 in common shares - Investing.com India

Nov 15, 2024

Nov 15, 2024

Alpha Cognition director Leonard Mertz acquires $49,996 in shares - Investing.com

Nov 15, 2024

Nov 15, 2024

Alpha Cognition Inc (ACOG-CN) QuotePress Release - The Globe and Mail

Nov 15, 2024

Nov 14, 2024

Alpha Cognition Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024

Nov 14, 2024

Alpha Cognition Inc (ACOGF) Quarterly 10-Q Report - Quartzy

Nov 14, 2024

Nov 12, 2024

Canada market stock losers: Tidewater Renewables Ltd. looses 12.43% while Rektron Group Inc dips by 10.33% during mid day trading - Business Upturn

Nov 12, 2024

Nov 12, 2024

Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing - Business Wire

Nov 12, 2024

Nov 06, 2024

Canada Market Top Losers: AYR Wellness down 47.30%, Trulieve Cannabis falls 40%, - Business Upturn

Nov 06, 2024

Nov 01, 2024

Alpha Cognition Inc. announced that it has received $4.545 million in funding - Marketscreener.com

Nov 01, 2024

Oct 31, 2024

Alpha Cognition Plans Nasdaq Listing and $25M Offering - TipRanks

Oct 31, 2024

Oct 28, 2024

Xavier Creative House Hires Jami Rogers as Vice President of Sales & Marketing - citybiz

Oct 28, 2024

Oct 21, 2024

Alpha Cognition Announces Appointment of VP Finance and Accounting - Business Wire

Oct 21, 2024

Oct 15, 2024

Alpha Cognition Inc (ACOGF) QuotePress Release - The Globe and Mail

Oct 15, 2024

Oct 04, 2024

Alpha Cognition Announces Executive Shake-up & Drug Approval - TipRanks

Oct 04, 2024

Oct 03, 2024

Alpha Cognition Announces Change of Officer - Business Wire

Oct 03, 2024

Oct 01, 2024

Spartan Capital Securities Serves as Selling Group Member - GlobeNewswire

Oct 01, 2024

Sep 25, 2024

Alpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge Financing - BioSpace

Sep 25, 2024

Aug 28, 2024

Alpha Cognition sets annual meeting for September 27 - Investing.com

Aug 28, 2024

Aug 20, 2024

July FDA approvals target Alzheimer's, myeloma and wet AMD - BioWorld Online

Aug 20, 2024

Aug 19, 2024

Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL® for Mild to Moderate Alzheimer’s Disease - Yahoo Finance

Aug 19, 2024

Aug 13, 2024

Alpha Cognition Inc. Adjusts Funding Strategy Amid Market Challenges - TipRanks

Aug 13, 2024

Aug 05, 2024

FDA approves AChEI ALPHA-1062 for Alzheimer’s disease treatment - News-Medical.Net

Aug 05, 2024

Jul 31, 2024

Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease - Seeking Alpha

Jul 31, 2024

Jul 30, 2024

FDA favors Zunveyl, Alzheimer's therapy showing better tolerability - Alzheimer's News Today

Jul 30, 2024

Jul 29, 2024

FDA approves Alpha Cognition's Zunveyl to treat Alzheimer's disease | 2024-07-29 | Investing News - Stockhouse Publishing

Jul 29, 2024

Jul 23, 2024

Breakeven On The Horizon For Alpha Cognition Inc. (CSE:ACOG) - Simply Wall St

Jul 23, 2024

Jul 16, 2024

Alpha Cognition upgraded at Raymond James - Cantech Letter

Jul 16, 2024

Jul 05, 2024

Early Inflammation Linked to Midlife Cognitive Decline - Neuroscience News

Jul 05, 2024

Jul 02, 2024

What’s Coming Down the Pike: Drug Approvals in the Second Half of ’24 - Managed Healthcare Executive

Jul 02, 2024

May 14, 2024

Alpha Cognition Announces First Quarter of 2024 Results and Provides Corporate Update - Business Wire

May 14, 2024

Apr 18, 2024

Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer’s (NASDAQ:CGTX) - Seeking Alpha

Apr 18, 2024

Apr 03, 2024

Alpha Cognition Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update - Yahoo Finance

Apr 03, 2024

Apr 02, 2024

Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now - GlobeNewswire

Apr 02, 2024

Feb 22, 2024

Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease - Yahoo Finance

Feb 22, 2024

Feb 12, 2024

Alpha Cognition Provides Business Update - Business Wire

Feb 12, 2024

Dec 22, 2023

Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering - Yahoo Finance

Dec 22, 2023

Dec 07, 2023

Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease - Business Wire

Dec 07, 2023

Sep 14, 2023

BioNTX iC3 Summit to Fuel North Texas Life Science Ecosystem, Honor 8 Rising Stars - dallasinnovates.com

Sep 14, 2023

Feb 10, 2023

Alpha Cognition gets rating downgrade from Raymond James - Cantech Letter

Feb 10, 2023

Jan 09, 2023

Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer - PR Newswire

Jan 09, 2023

Sep 13, 2022

Data: ALPHA-1062 a Bioequivalent to Approved Therapy Razadyne - Alzheimer's News Today

Sep 13, 2022

Apr 12, 2022

Progranulin Gene Therapy Shows Promise in Preclinical Studies - ALS News Today

Apr 12, 2022

Oct 25, 2021

Alpha Cognition could have a best-in-class Alzheimer’s drug, iA Capital says - Cantech Letter

Oct 25, 2021

Oct 02, 2020

Pharmaceutical Entrepreneur Fred Sancilio Speaks on His Vast Industry Experience - Thrive Global

Oct 02, 2020